Anti-CD81 antibodies reduce migration of activated T lymphocytes and attenuate mouse experimental colitis.

ABSTRACT: Inflammatory bowel disease (IBD) is an immunological disease associated with CD4⁺ T cell activation in the intestines. CD81 is a regulator of the immune system with multiple biological functions. Therefore, in this study, we assessed the contribution of CD81 to IBD pathophysiology and the therapeutic efficacy of anti-CD81 antibodies. Expression of CD81 was increased on activated T cells in vitro and in colitic mice in vivo. Therapeutic effects of anti-CD81 antibodies on colitic symptoms and inflammation were evaluated in mice with colitis, including long-term effects of the antibodies. Treatment with anti-CD81 antibodies improved colitis scores, reduced colon shortening, decreased loss of body weight, and resulted in fewer pathological changes of the colon in colitic mice. Moreo

SUBMITTER: Hasezaki T 

PROVIDER: S-EPMC7181603 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature